Short Interest in Femasys Inc. (NASDAQ:FEMY) Drops By 8.9%

Femasys Inc. (NASDAQ:FEMY) was the recipient of a significant drop in short interest during the month of July. As of July 15th, there was short interest totalling 920,600 shares, a drop of 8.9% from the June 30th total of 1,010,000 shares. Approximately 4.5% of the company’s shares are short sold. Based on an average daily volume of 171,000 shares, the short-interest ratio is currently 5.4 days.

Hedge Funds Weigh In On Femasys

A hedge fund recently raised its stake in Femasys stock. Clear Creek Financial Management LLC increased its position in Femasys Inc. (NASDAQ:FEMY) by 30.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 309,274 shares of the company’s stock after purchasing an additional 72,505 shares during the period. Clear Creek Financial Management LLC owned approximately 1.40% of Femasys worth $479,000 at the end of the most recent reporting period. 65.27% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Femasys in a report on Thursday, June 20th.

Femasys Stock Down 1.8 %

Femasys stock traded down $0.02 on Thursday, hitting $1.11. 23,085 shares of the stock traded hands, compared to its average volume of 418,090. The company has a current ratio of 8.43, a quick ratio of 8.02 and a debt-to-equity ratio of 0.29. The firm has a market cap of $24.66 million, a P/E ratio of -1.35 and a beta of -2.81. The business’s fifty day simple moving average is $1.12 and its 200 day simple moving average is $1.29. Femasys has a 1 year low of $0.25 and a 1 year high of $4.75.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.05. The business had revenue of $0.27 million during the quarter, compared to analyst estimates of $0.30 million. Femasys had a negative return on equity of 104.06% and a negative net margin of 1,420.59%. As a group, sell-side analysts forecast that Femasys will post -0.72 earnings per share for the current year.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.